Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma

Affiliations

¹ Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: nsingla2@jhmi.edu.
² Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Comment

Nirmish Singla et al. Eur Urol. 2021 Jan.

. 2021 Jan;79(1):e28.

doi: 10.1016/j.eururo.2020.09.013. Epub 2020 Sep 30.

¹ Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: nsingla2@jhmi.edu.
² Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

No abstract available

Comment on

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E. Birtle A, et al. Lancet. 2020 Apr 18;395(10232):1268-1277. doi: 10.1016/S0140-6736(20)30415-3. Epub 2020 Mar 5. Lancet. 2020. PMID: 32145825 Free PMC article. Clinical Trial.